MAP Pharma raises $50M for respiratory and CNS disease treatments

MAP Pharmaceuticals, a Mountain View, Calif, developer of treatments for respiratory and central-nervous-system diseases, said it raised $50 million in a fourth round of venture funding.

See statement here.

New investor, the D.E. Shaw group, joined previous investors, including Perseus-Soros Biopharmaceutical Fund, Pequot Ventures, Brookside Capital, Bay City Capital and Skyline Ventures.

MAP recently completed the second phases of clinical trials for its treatments for pediatric asthma and migraine. The company plans to use the new funds to advance into next-stage trials for both treatments.